AI 聊天
Loading data for ICCM — first visit, this takes a few seconds.

IceCure Medical Ltd

ICCM · NasdaqCM · USD

1.99 -0.07 (-3.40%)

收盤價: Sep 18, 2026, 8:00 PM

2.02 +3.06%

盤後: 7:29 PM

市值
$6.72M
下次財報日期
Nov 18, 2026

IceCure Medical Ltd(ICCM)股價、分析與資料

您正在查看免費總覽

建立免費帳戶即可查看該標的的財務、選擇權、預測及全部內容。

內在價值

估值模型屬於 Pro 功能。登入或升級後可查看完整分析。

查看方案 →

分析師預測

股票預測 →

分析師預測無法取得

12個月目標價 · n/a 位分析師

分析師共識: n/a

間隔:1D
正在載入K線和訊號…

財務表現

查看財務 →

正在載入...

最新財報

已通報較預期YoY 變更
營收$907.0Kn/a+72.76%
EPS-$1.37$0.00+23.89%

下次財報

開盤前。

估計 · 升級 →

查看財報詳情 →

指標

買價
1.49
市值
6.72M
淨利(ttm)
-16.9M
0.45
-6.78
n/a
-0.59
P/B (ttm)
0.56
P/S (ttm)
1.70
財報日期
Nov 18, 2026
賣價
2.59
成交量
158,474
20 日平均成交量
894,377
開盤價
2.11
前收盤價
2.06
當日區間
1.96 - 2.16
52 週範圍
1.96 - 42.00
股利
n/a
除息日
n/a

關於 IceCure Medical Ltd

查看公司資料 →
IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposables, including CryoProbes needles, and guiding needles/introducers; and IceSense3 system for ablation indications in urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MSense, a multi probe system for the treatment of multiple and larger tumors. The company serves hospitals, interventional radiological centers, ambulatory centers, and private clinics. IceCure Medical Ltd was incorporated in 2006 and is headquartered in Caesarea, Israel. Medical Devices · Healthcare

IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposables, including CryoProbes needles, and guiding needles/introducers; and IceSense3 system for ablation indications in urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MSense, a multi probe system for the treatment of multiple and larger tumors. The company serves hospitals, interventional radiological centers, ambulatory centers, and private clinics. IceCure Medical Ltd was incorporated in 2006 and is headquartered in Caesarea, Israel.

類股 Healthcare
IPO 日期 Aug 26, 2021
員工 67
證券交易所 NasdaqCM
股票代號 ICCM